Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 17/20 | 1.00 |
| ▸ | RXRA | P19793 | 3/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17502318 | 0.91 | KCNH2 (0.91) | KCNH2 | |
| SCHEMBL17502254 | 0.88 | KCNH2 (1.00) | KCNH2RXRAGRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL21802309 | 0.87 | KCNH2 (0.98) | KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL17502274 | 0.85 | KCNH2 (1.00) | KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL17502282 | 0.85 | KCNH2 (1.00) | KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL17502333 | 0.83 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL17502272 | 0.83 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL17502291 | 0.83 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL4432838 | 0.83 | KCNH2 (0.70) | KCNH2RXRAGRIN1GRIN2B | |
| SCHEMBL17502207 | 0.82 | KCNH2 (1.00) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180329-B1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | claimed |
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-06-18 | — | — | US | claimed |
| US-20180282305-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2018-10-04 | — | — | US | claimed |
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | claimed |
| EP-3180329-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| WO-2016025917-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-02-18 | — | — | WO | claimed |
| EP-3180329-B1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-3180329-B1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180282305-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2018-10-04 | — | — | US | disclosed |
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981950-B2 | Triazoles as NR2B receptor inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016025917-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282305-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | GRIN2B, GRIN1, GRIN3A | KCNH2 2545/4885RXRA 1823/4885GRIN1 2/4885 |
| US-20170226087-A1 | TRIAZOLES AS NR2B RECEPTOR INHIBITORS | GRIN2B, GRIN1, GRIN3A | KCNH2 2545/4885RXRA 1823/4885GRIN1 2/4885 |
| US-10323021-B2 | Triazoles as NR2B receptor inhibitors | GRIN2B, GRIN1, GRIN3A | KCNH2 2545/4885RXRA 1823/4885GRIN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.